Generic substitution of antiepileptic drugs

Détails

ID Serval
serval:BIB_889D551BB212
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Generic substitution of antiepileptic drugs
Périodique
Expert Rev Neurother
Auteur⸱e⸱s
Sander J. W., Ryvlin P., Stefan H., Booth D. R., Bauer J.
ISSN
1744-8360 (Electronic)
ISSN-L
1473-7175
Statut éditorial
Publié
Date de publication
12/2010
Volume
10
Numéro
12
Pages
1887-98
Langue
anglais
Notes
Sander, Josemir W
Ryvlin, Philippe
Stefan, Hermann
Booth, Daniel R
Bauer, Jurgen
eng
Review
England
Expert Rev Neurother. 2010 Dec;10(12):1887-98. doi: 10.1586/ern.10.163.
Résumé
Substitution of antiepileptic drugs with generic formulations may affect individual people, as well as healthcare systems. Analyses of large medical claims databases suggest that generic substitution of antiepileptic drugs is associated with increased morbidity and greater use of healthcare resources. While a single brand-to-generic switch may be associated with a slight increase in overall medical costs, multiple switches may be associated with higher costs, perhaps because different generic agents are not required to be bioequivalent to each other. Generic substitution also affects the individual: along with the possible increased risk of seizures or adverse events, inconsistency of supply may make the medication appear unfamiliar, thus discouraging adherence. Importantly, substitution is often carried out at the dispensing level, without the knowledge or consent of physicians and affected individuals. Therefore, regulatory and professional bodies advocate that substitution should not be carried out without specific counseling of the individual by healthcare professionals on the details and implications of the change.
Mots-clé
Anticonvulsants/adverse effects/*economics/*therapeutic use, Drug Substitution/adverse effects/*economics, Drugs, Generic/adverse effects/*economics/*therapeutic use, Epilepsy/*drug therapy, Humans, Male, Medication Adherence, Therapeutic Equivalency
Pubmed
Création de la notice
29/11/2018 12:37
Dernière modification de la notice
20/08/2019 14:47
Données d'usage